- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01223079
Use of r-hLH (Luveris) in Donors Previously Treated With r-hFSH (Gonal F)
Use of r-hLH (Luveris) Late Follicular Phase for Controlled Ovarian Stimulation (COS) in Donor Patients Previously Treated With r-hFSH (Gonal F)in a Long Luteal Downregulated Cycle With GnRH Agonist. A Cross-over Study
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
While the role of FSH is considered the fundamental driver of folliculogenesis, the role of LH in this process is more controversial. FSH is associated with stimulating growth and recruitment of follicles while LH is associated with the selection of dominant follicles destined for ovulation. We will use an open, prospective, cross-over study to compare the safety and efficacy of two different treatment protocols for controlled ovarian stimulation in egg donors.
20 participants will undergo two cycles of stimulation. The first one will be with r-hFSH though the cycle and the second with r-hFSH then r-hLH. The participants will have 1 month rest cycle between the treatment cycles. r-hFSH doses will be adjusted according to patient response. r-hLH dosing will begin when there are 2 follicles greater than or equal to 14mm in diameter. The does will be 300IU/day and continue until the day of r-hCG administration.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
New Jersey
-
Morristown, New Jersey, Forenede Stater, 07960
- Reproductive Medicine Assoicates of New Jersey
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age less than or equal to 32 years old
- BMI<35
- Eligible for controlled ovarian simulation
- No PCO-type ovaries (PCO by USS image, >2.1 LH;FSH ratio on cycle day 3, insulin resistance, increase of testosterone over free testosterone)
- Meet all requirements for becoming an egg donor
- Willingness and ability to participate and comply with study protocol for the duration of the study
- Baseline FSH<11
Exclusion Criteria:
- Clinically significant systemic disease
- Any contraindication to gonadotropin therapy
- LH:FSH ratio greater than 3
- Pregnancy in the past 3 months
- Any medical condition which, in the judgment of the investigator may interfere with the absorption, distribution, metabolism or excretion of the drug
- Simultaneous participation in another clinical trial
- Known active substance abuse, including tobacco and alcohol (>10 cigarettes/day)
- Refusal or inability to comply with protocol
- Known poor ovarian response
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Crossover opgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Andet: r-hFSH (Gonal F)
Patients will be treated with r-hFSH throughout the stimulation phase of their first cycle until r-hCG administration.
|
r-hFSH dose to be determined by the patient's primary doctor and adjusted according to their response
Andre navne:
|
Andet: r-hFSH (Gonal F) and r-hLH (Luveris)
Patients will be treated with r-hFSH only until they have 2 follicles greater than or equal to 14mm.
Patients will then bring 300IU/day of r-hLH until r-hCG administration.
|
Patients will begin r-hLH at 300IU/day when there are 2 follicles greater than or equal to 14mm.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Safety and efficacy of r-hFSH protocol
Tidsramme: 6 months
|
Evaluation of the safety and efficacy of r-hFSH for controlled ovarian stimulation in the same patients.
|
6 months
|
Safety and efficacy of r-hFSH + r-hLH protocol
Tidsramme: 6 months
|
Evaluation of the safety and efficacy of r-hFSH for controlled ovarian stimulation in the same patients.
|
6 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Number of oocytes retrieved
Tidsramme: 6 months
|
Evaluation of the number of oocytes obtained as a function of stimulation protocol.
|
6 months
|
Quality of embryos obtained
Tidsramme: 6 months
|
Evaluation of pregnancy rates (clinical and ongoing), delivery rates, multiple pregnancy rates and the number of cancelled cycles.
|
6 months
|
Incidences of ovarian hyperstimulation syndrome
Tidsramme: 6 months
|
Evaluation of the potential adverse effects associated with ovarian stimulation
|
6 months
|
Quality of oocytes obtained
Tidsramme: 6 months
|
Evaluation of the quality of oocytes obtained as a function of stimulation protocol.
|
6 months
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Richard T Scott, MD, Reproductive Medicine Associates of New Jersey
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 20052361
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med r-hFSH
-
Finox AGAfsluttet
-
Finox AGAfsluttet
-
Merck KGaA, Darmstadt, GermanyAfsluttet
-
Merck KGaA, Darmstadt, GermanyMerck Serono S.P.A., ItalyAfsluttetReproduktionsteknikker, assisteretItalien
-
Medical University of ViennaSuspenderet
-
Merck KGaA, Darmstadt, GermanyMerck Pte. Ltd., SingaporeAfsluttet
-
Merck KGaA, Darmstadt, GermanyMerck, S.L., SpainAfsluttet
-
Merck KGaA, Darmstadt, GermanyAfsluttet
-
Merck KGaA, Darmstadt, GermanyAfsluttet
-
Centro Riproduzione e AndrologiaAfsluttetHypogonadotropisk hypogonadismeItalien